A medicine that sidesteps the brain’s dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.
(Image credit: Steve Belkowitz)
A new kind of drug for schizophrenia promises fewer side effects from NPR Sydney Lupkin
